Using a Treatment-tradeoff Method to Elicit Preferences for the Treatment of Locally Advanced Non-Small-cell Lung Cancer

The study was designed to evaluate a treatment-tradeoff method for its potential in helping lung cancer patients make treatment decisions. A treatment-tradeoff interview was conducted to determine how patients weighed potential survival benefits against the potential toxicities of different treatment options: 1) low-dose versus high-dose radiotherapy, and 2) high-dose radiotherapy versus combination chemo-radiotherapy. Fifty-six patients who had experienced cancer and 20 clinic staff participated; twenty of these participants repeated the interview in an assessment of response consistency. The treatment-tradeoff method proved feasible: all staff and 53 of the 56 patients were able to complete the process. A wide range of threshold scores across participants was observed for both tradeoffs. Sixty percent of the patients would accept the more toxic combination therapy over high-dose radiotherapy if the former offered a 10% absolute improvement in three-year survival. The method also proved reliable: test-retest correlations were high (τ ranged from 0.7 to 0.87 and r from 0.82 to 0.94) and test-retest mean score differences were low (1.3-4.2). The most clinically useful mea sure of consistency was a "preference consistency" index, which revealed that most patients declared the same treatment preference at test and retest. The authors conclude that, while there is great interindividual variability in willingness to accept aggressive treatments for lung cancer, patients' values can be consistently elicited with the tradeoff method. The method has potential for clinical application in decision making and for health-care policy development. Key words: treatment tradeoffs; patient decision making; lung cancer; policy. (Med Decis Making 1998;18:256-267)

[1]  B. O'Sullivan,et al.  The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. , 1986, British Journal of Cancer.

[2]  D. Streiner,et al.  Health Measurement Scales: A practical guide to thier development and use , 1989 .

[3]  R. Clemen,et al.  Beyond expected utility: rethinking behavioral decision research. , 1994, Psychological bulletin.

[4]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[5]  B. McNeil,et al.  Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. , 1981, The New England journal of medicine.

[6]  H. Llewellyn-Thomas,et al.  Patients' willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation. , 1991, Social science & medicine.

[7]  H. Llewellyn-Thomas,et al.  Patients versus surrogates: whose opinion counts on ethics review panels? , 1989, Clinical research.

[8]  D. Tritchler,et al.  Communicating probabilistic information to cancer patients: is there 'noise' on the line? , 1991, Social science & medicine.

[9]  N. Boyd,et al.  Whose Utilities for Decision Analysis? , 1990, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  O. Nascimben,et al.  Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. , 1992, International journal of radiation oncology, biology, physics.

[11]  B. McNeil,et al.  Fallacy of the five-year survival in lung cancer. , 1978, The New England journal of medicine.

[12]  J M Bland,et al.  Statistical methods for assessing agreement between two methods of clinical measurement , 1986 .

[13]  M. Brundage,et al.  Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966-1993. , 1996, Journal of clinical epidemiology.

[14]  P. Price,et al.  Important advances in oncology 1996 , 1997 .

[15]  W. Mackillop,et al.  An empirical approach to informed consent in ovarian cancer. , 1996, Journal of clinical epidemiology.

[16]  N F Boyd,et al.  Eliciting preferences for alternative drug therapies in oncology: influence of treatment outcome description, elicitation technique and treatment experience on preferences. , 1987, Journal of chronic diseases.

[17]  K. Propert,et al.  A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. , 1990, The New England journal of medicine.

[18]  Douglas G. Altman,et al.  Measurement in Medicine: The Analysis of Method Comparison Studies , 1983 .

[19]  W. Curran,et al.  Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. , 1995, Journal of the National Cancer Institute.

[20]  R. Arriagada,et al.  Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. , 1991, Journal of the National Cancer Institute.

[21]  Green Mr Chemotherapy and radiation in the nonoperative management of stage III non-small-cell lung cancer: the right chemotherapy works in the right setting. , 1993 .

[22]  T. Tong,et al.  Cancer statistics, 1994 , 1994, CA: a cancer journal for clinicians.

[23]  M. Kendall,et al.  The advanced theory of statistics , 1945 .

[24]  LII. a primer on quantitative indexes of association , 1980, Clinical pharmacology and therapeutics.

[25]  M. Brundage,et al.  Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Stiggelbout,et al.  Test-Retest Reliabilities of Two Treatment-preference Instruments in Measuring Utilities , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[27]  C. Mountain The new International Staging System for Lung Cancer. , 1986, The Surgical clinics of North America.

[28]  M. Brundage,et al.  Decision analysis in locally advanced non-small-cell lung cancer: is it useful? , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J W Denham,et al.  Treatment and planning decisions in non-small cell carcinoma of the lung: an Australasian patterns of practice study. , 1992, Clinical oncology (Royal College of Radiologists (Great Britain)).

[30]  K R Hammond,et al.  How Convergence of Research Paradigms Can Improve Research on Diagnostic Judgment , 1996, Medical decision making : an international journal of the Society for Medical Decision Making.

[31]  T. Priestman,et al.  The Royal College of Radiologists' Fractionation Survey. , 1989, Clinical oncology (Royal College of Radiologists (Great Britain)).

[32]  G W Torrance,et al.  Utility approach to measuring health-related quality of life. , 1987, Journal of chronic diseases.

[33]  H. Bartelink,et al.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. , 1992, The New England journal of medicine.

[34]  W. Mackillop,et al.  Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. K. Benedetti,et al.  Sampling Behavior of Tests for Correlation in Two-Way Contingency Tables , 1977 .

[36]  P. Rubin,et al.  Long‐term observations of the patterns of failure in patients with unresectable non‐oat cell carcinoma of the lung treated with definitive radiotherapy report by the radiation therapy oncology group , 1987, Cancer.

[37]  B. O'Sullivan,et al.  Non-small cell lung cancer: how oncologists want to be treated. , 1987, International journal of radiation oncology, biology, physics.

[38]  C D Naylor,et al.  Using a Trade-off Technique to Assess Patients' Treatment Preferences for Benign Prostatic Hyperplasia , 1996, Medical decision making : an international journal of the Society for Medical Decision Making.

[39]  B. O'Sullivan,et al.  Controversies in the management of non-small cell lung cancer: the results of an expert surrogate study. , 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.